Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Time to relinquish the concept of “resectability” in mesothelioma?
2. Repotrectinib continues to demonstrate durable efficacy in patients with ROS1+ NSCLC
5. Benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage SCLC